Información del artículo
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Boletín epidemiológico semanal. Centro Nacional de Epidemiología 1999. Vol. 7 Nº 16/169-176.
[2.]
Fisher B..
The evolution of paradigms for the management of breast cancer; a personal perspective.
Cancer Res, 52 (1992), pp. 2371-2383
[3.]
Early Breast Cancer Trialists' Collaborative Group.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deats among 75000 women.
Lancet, 339 (1992), pp. 1-15
[4.]
Early Breast Cancer Trialists' Collaborative Group.
Polychemotherapy for early breast cancer: an overview of randomised trials.
Lancet, 352 (1998), pp. 930-942
[5.]
Fisher B., Dignam J., Mamounas E.P., Costantino J.P., Wickerham D.L., Redmond C..
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor negative tumors; eight-year results from NSABP B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil.
J Clin Oncol, 14 (1996), pp. 1982-1992
[6.]
Mansour E.G., Gray R., Shatila A.H., Tormey D.C., Cooper M.R., Osborne C.K..
Survival advantage of adyuvant chemotherapy in high-risk node-negative breast cancer: ten-year analisys an intergroup study.
J. Clin. Oncol, 16 (1998), pp. 3486-3492
[7.]
Fisher B., Dignam J., Wolmark N., De Cillis A., Emir B., Wickerham D.L., et al.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
J. Natl. Cancer Inst., 89 (1997), pp. 1673-1682
[8.]
Consensus Conference: Adyuvant Chemotherapy for Breast Cancer.
Jama, 254 (1985), pp. 3461-3463
[9.]
NHI Consensus Conference: Treatment of Early Stage Breast Cancer.
Jama, 265 (1991), pp. 391-395
[10.]
Adjuvant therapy for breast cancer. National Institutes of Health. Consensus Development Conference Statement. Nov 1-3, 2000. http.//odp.od.nih. gov/consensus/ cons/114/114_statement.htm.
[11.]
Glick J.H..
Meeting highlights: Adjuvant therapy for breast cancer.
J Nat Cancer Inst, 84 (1992), pp. 1479-1485
[12.]
Goldhrirsch A., Wood W.C., Senn H.J., Glick J.H., Gelber R.D..
Meeting highlights: International Consensus Panel on The treatment of primary breast cancer.
J Natl Cancer Inst, 87 (1995), pp. 1441-1445
[13.]
Goldhirsch A., Glick J.h., Gelber R.D., Senn H.J..
Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. VI International Consensus Conference on Primary Treatment of the breast.
J. Natl. Cancer Inst, 1998,, 21 (1990), pp. 1601-1608
[14.]
Ludwig Breast Cancer Study Group.
Combination adjuvant chemotherapy for node-positive breast cancer: Inadecuaty of a single perioperative cicle.
N Eng J Med, 319 (1988), pp. 677-683
[15.]
Early Breast Cancer Trialists' Collaborative Group.
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet, 351 (1998), pp. 1451-1467
[16.]
Clahsen P.C., Van De Velde C.J., Julien J.P., Floiras J.L., Delozier T., Mignolet F.Y., et al.
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer: A European Organization for Research and Treatment of Cancer Breast. Cancer Cooperative Group Study.
J Clin. Oncol, 14 (1996), pp. 745-753
[17.]
Moliterni A., Bonadonna G., Valagussa P., Ferrari L., Zambeti M..
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorrubicin in the adyuvant treatment of resec-table breast cancer with one to three positive axillary nodes.
J. Clin. Oncol, 9 (1991), pp. 1124-1130
[18.]
Bonadonna G., Zambetti M., Valagussa O..
Sequential or alternating doxorubicin and CMF regimen in breast cancer with more than three positive nodes. Ten-years results.
Jama, 273 (1995), pp. 5472-5477
[19.]
Fisher B., Brown A.M., Dimitrov N.V., Poissin R., Redmond C., Margolese R.G..
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the NSABP B-15.
J Clin. Oncol, 8 (1990), pp. 1483-1496
[20.]
Thor A.D., Berry D.A., Budman D.R., Muss H.B., Kute T., Henderson I.C., et al.
erbB-2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
J Natl. Cancer Inst, 90 (1998), pp. 1346-1360
[21.]
Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D..
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
J. Natl. Cancer Inst, 90 (1998), pp. 1361-1370
[22.]
Budman D.R., Berry D.A., Cirrincione C.T., Hendensor I.C., Wood W.C., Weiss R.B..
For the Cancer and Leukemia Group B. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.
J. Natl. Cancer Inst, 90 (1998), pp. 1205-1211
[23.]
Hryniuk W., Levine M.N..
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
J. Clin. Oncol, 4 (1996), pp. 1162-1170
[24.]
Wood W.c., Budman D.R., Korzum A.H., Cooper M.R., Younger J., Hart R.D..
Dose and intensity of adjuvant chemotherapy for stage II, node-positive breast cancer.
N Eng J Med, 330 (1994), pp. 1253-1259
[25.]
Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., et al.
Dose an Dose Intensity as determinants of outcome in the adjuvant treatment of breast cancer.
J Natl. Cancer Inst., 90 (1998), pp. 1205-1211
[26.]
Fisher B., Anderson S., Wickerman D.L., De Cillis A., Dimitrov N..
Mamounas: Increased intensification and total dose of ciclophosphamide in a doxorubicin-ciclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Proyect B-22.
J Clin. Oncol.,, 15 (1997), pp. 1858-1869
[27.]
Fisher B., Anderson S., DeCillis A., Dimitrov N., Atkins J.N., Fehrenbacher L..
Further evaluation of intensified and increased total dose of ciclop-hosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Proyect B-25.
J. Clin. Oncol.,, 17 (1999), pp. 3374-3388
[28.]
Peter WP, Cancer and Leukemia Group B:NCI High Priority Clinical Trial. Phase III Randomized Comparation of High-dose Chemotherapy with Autologous Marrow and Peripheral Stem Cell Support vs Standard-Dose Chemotherapy Following Adjuvant Chemotherapy in Women with Stage II/IIIA Breast Cancer with at Least 10 Positive Axillary Nodes (Summary Last Modified 09/98), CLB-9082, clinical trials, closed, 05/29/1998.
[29.]
Tallman MS, Eastern Cooperative Oncology Group: NCI High Priority Clinical Trials. Phase III Randomized Study of Adjuvant CAF (Cyclophosphamide/Doxorubivin/Fluorouracil) vs Adjuvant CAF Followed by Intensification with High-Dose Cyclophosphamide/thiotepa plus Autologous Stem Cell Rescue in Women with Stage II/III Breast Cancer At High Risk of Recurrence (Summary Last Modified 12/98), Est-2190, clinical trials, closed, 08/03/1998.
[30.]
Peters W, Rosner G, et al. For CALGB, SWOG, and NCIC: A prospective randomized comparation of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Pro Am Soc Clin Oncol, 1999;2a(3).
[31.]
The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autogous bone marrow stem cell versus dose escalated and tailored FEC therapy. Pro Am Soc Clin Oncol, 1999;2a(3).
[32.]
Rodenhuis S., Richel D.J., Van Der Wall E., Schornagel J.H., Baars J.W., Koning C.C., et al.
Randomized trial of high-dose chemotherapy with autologous stem cell recue for breast cancer with extensive axillary lymph-node involvement.
Lancet,, 352 (1998), pp. 515-521
[33.]
David McNamee.
High-dose chemotherapy positive in breast-cancer trial.
Lancet, 355 (2000), pp. 1973
[34.]
Fisher B., Dignam J., Mamounas E.P., Costantino J.P., Wickerham D.L., Redmon, et al.
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors; eight-years results from National Surgical Adjuvant Breast and Bowel Proyect (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluo-rouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
J Clin. Oncol.,, 14 (1996), pp. 1982-1992
[35.]
Henderson IC, Berry D, Demetri G, Cirrincione C; Goldstein L; Martino S; et. al.: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer. Proc Am Soc Clin Oncol, 1998;101a (390a).
[36.]
Ueno N.T., Buzdar A.U., Singletary S.E., Ames F.C., McNeese M.D., Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M Holmes F.A., et al.
D.
Anderson Cancer Center. Cancer Chemotherapy and Pharmacology,, 40 (1997), pp. 321-329
[37.]
Berg C.D., Swain S.M..
Results of concomitantly administered chemoradiation for locally advanced non inflammatory breast cancer.
Seminars in Radiation Oncology,, 4 (1994), pp. 226-235
[38.]
Fisher B., Bryan J., Wolmark N., Mamounas E., Rosenthal S.N..
De Wys: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
J Nat Cancer Inst, 16 (1998), pp. 2672-2685
[39.]
Kuukasjarvi T., Kononen J., Helin H., Holli K., Isola J..
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
J. Clin. Oncol, 14 (1996), pp. 2584-2589
[40.]
Perry M.C., Kardinal C.G., Korzun A.H., Ginsberg S.J., Raich P.C., Holland, et al.
Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
J Clin. Oncol.,, 5 (1987), pp. 1534-1545
[41.]
Honig S.F., et al.
Hormonal therapy and chemotherapy.
Diseases of the Breast, pp. 669-734
[42.]
Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U..
Log-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
J Clin. Oncol.,, 14 (1996), pp. 2197-2205
[43.]
Ranson M.R., Carmichael J., O’ Byrne K., Stewart S., Smith D., Howel A..
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
J. Clin. Oncol, 15 (1997), pp. 3185-3191
[44.]
Blumm J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al.
Multicenter phase II study of capecitabine in paclitaxel-refractory metastasic breast cancer.
J. Clin. Oncol., 17 (1999), pp. 485-493
[45.]
Degardin M., Bonneterre J., Hecquet B., Pion J.M., Adenis A., Horner A..
Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer.
Ann. Oncol.,, 5 (1994), pp. 423-426
[46.]
Carmichael J., Walling J..
Advanced breast cancer: investigational role of gemcitabine.
European Journal of Cancer, 33 (1997), pp. S27-S30
[47.]
Tranum B.L., McDonald B., Thigpen T., Vaughn C., Wilson H., Maloney T., et al.
Adriamicin combinations in advanced breast cancer: a Southwest Oncology Group study.
Cancer, 49 (1982), pp. 835-839
[48.]
Misset J.L., Dieras V., Gruia G., Bourgeois H., Cvitkovic E., Kalla S., et al.
Dose-finding study of docetaxel and doxorubicin in firts-line treatment of patients with metastatic breast cancer.
Ann Oncol, 10 (1999), pp. 553-560
[49.]
Buzdar A.U., Kau S.W., Smith T.L..
Hortobagy: Ten year results of FAC adjuvant chemotherapy trial in breast cancer.
Am. J. Clin. Oncol, 12 (1989), pp. 123-128
[50.]
Tormey D.C., Gelman R., Band P.R., Sears M., Rosenthal S.N..
De Wys,: Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.
Cancer, 50 (1982), pp. 1235-1244
[51.]
Nabholtz J.M., Gelmon K., Bontebal M., Spielman M., Catimel G., Conte P., et al.
Multicenter randomized comparative study of two doses of paclitaxel in patients with metas-tatic breas cancer.
J Clin Onc, 14 (1996), pp. 1858
[52.]
Nabholtz J.M., Thuerlimann B., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., et al.
Taxotere (T) versus Mytomicin C*Vinbastine (MV) in patients with metastatic breast cancer who have failed an antracicline containing regimen: preliminary results of a randomized phase III study.
Oncology, 11 (1997), pp. 25-30
[53.]
Wilson W.H., Berg S.L., Bryan G., Wittes R.E., Bates S., Fojo A., et al.
Paclitaxel in doxorubicin-refractary breast cancer: A phase I/II trial of 96 hour infusion.
J Clin Onc, 12 (1994), pp. 1621
[54.]
Seidman A.D., Reichman B.S., Crown, Yao T.J., Currie V., Hakes T.B., et al.
Paclitaxel as second and subsequent therapy for metasytatic breast cancer: Activity independent of prior anthraci-cline response.
J Clin Onc, 13 (1995), pp. 1621
[55.]
Paridaens R, Bruning P, Klinj J; Gamucci T; Biganzoli L; Van Vreckem A; et. al.: An EORTC crossover trial comparing single-agent Taxol and doxorubicine as first and second line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 1997; Abstr 539.
[56.]
Ravdin P.M., Burris H.A. 3rd, Cook G., Eisenberg P., Kane M., Bierman W.A., et al.
Phase II trial of docetaxel in advanced anthraciclin-resistant or antracenodione-resistant breast cancer.
J. Clin. Oncol, 13 (1995), pp. 2879
[57.]
Valero V.F., Holmes A., Walters R.S., Theriault R.L., Esparza L., Fraschini G., et al.
Phase II trial of docetaxel: a new highly effective antineo-plastic agent in the management of patients with antraciclin-resistant metastatic breast cancer.
J. Clin. Oncol, 13 (1995), pp. 2886-2894
[58.]
Hudis C.A., Seidman A.D., Crown J.P., Balmaceda C., Freilich R., Gilewski T.A., Hakes T.B., Currie V., Lebwohl D.E., Baselga J., Raptis G., Gollub M., Robles M., Bruno R., Norton L..
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
J. Clin. Oncol, 14 (1996), pp. 58-65
[59.]
Trudeau M.E., Eisenhauer E.A., Higgins B.P., Letendre F., Lofters W.S., Norris B.D., Vandenberg T.A., Delorme F., Muldal A.M..
Docetaxel in patients with metastatic breast cancer: a Phase II study of the national Cancer Institute of Canada-Clinical Trials Group.
J Clin Oncol, 14 (1996), pp. 422-428
[60.]
Sledge GW Jr, Neuberg D, Ingle J, Martina S, Wood W. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol, 1997; A2 (2).
[61.]
Honig S.F., et al.
Hormonal therapy and chemotherapi.
Diseases of the breast, pp. 669-734
[62.]
Perez E.A..
Current management of metastatic breast cancer.
Semin. Oncol, 26 (1999), pp. 1-10
[63.]
Falkson G., Gelman R.S., Pandya K.J., Osborne C.K., Tormey D., Cummings F.J., et al.
Eastern Cooperative Oncology Group Randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission followinginduction treatment.
J Clin. Oncol.,, 16 (1998), pp. 1669-1676
[64.]
Peters W.P., Jones R.B., Vrendenburgh J., et al.
A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM).
Proc Am Soc Clin Oncol, 15 (1996), pp. A149
[65.]
Muss H.B., Case L.D., Richards F I.I., White D.R., Cooper M.R., Cruz J.M., et al.
Interrupted versus continuous chemotherapy in patients with metastatic breast cancer.
N Eng J Med, 325 (1991), pp. 1342-1348
[66.]
Falkson G., Gelman R.S., Glick J., Falkson C.I., Harris J..
Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obained following doxorubicin induction treatment: an Eastern Cooperative Oncology Group study.
Ann Oncol, 3 (1992), pp. 768-770
[67.]
Stadtmauer E.A., O'Neill A., Goldsteine L.J., Crilley P.A., Mangan K.F., Ingle J.N., et al.
for the Philadelphia Bone Marrow Transplant Group: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metasta-tic breast cancer.
N Eng J Med, 342 (2000), pp. 1069-1076
Copyright © 2000. Academia de Ciencias Médicas de Bilbao